4Filed Jun 22, 8:00 PM ET
Mesa Labs (MLAB) CAO Lyndsey Crennen Exercises & Sells Shares
$MLAB · MESA LABORATORIES INC /CO/Research Summary
AI-generated summary of this SEC filing
Mesa Labs (MLAB) CAO Lyndsey Crennen Exercises & Sells Shares
What Happened
- Lyndsey Crennen, Chief Accounting Officer (CAO) of Mesa Labs (MLAB), converted/exercised derivative awards and received a total of 989 shares on June 18, 2026 (125 + 233 + 368 shares from derivative conversions and 263 shares from an award). The reported aggregate value of those acquired shares is $94,054 (based on $95.10 per share entries).
- On June 22, 2026 she sold 442 shares in an open-market transaction at $89.50 per share for $39,560. The filing shows disposals of the derivative instruments at $0.00 tied to the conversions. Footnotes indicate the sale of 442 shares was to cover taxes related to the vesting of RSUs and PSUs and was executed under a Rule 10b5-1 plan.
Key Details
- Transaction dates and prices:
- June 18, 2026: Exercise/conversion of derivatives — 125 @ $95.10 ($11,888); 233 @ $95.10 ($22,158); 368 @ $95.10 ($34,997); Award — 263 @ $95.10 ($25,011).
- June 22, 2026: Open-market sale — 442 @ $89.50 = $39,560 (to cover taxes; executed under a 10b5-1 plan).
- Derivative disposals of 125, 233 and 368 shares are reported at $0.00 reflecting conversion of the derivative instruments into shares.
- Net effect: 989 shares acquired less 442 shares sold = 547 net shares retained from these transactions.
- Shares owned after transaction: not specified in the Form 4 filing.
- Notable footnotes: RSUs/PSUs vesting schedules (F1–F6) and F7 confirms the 442-share sale was tax withholding under a 10b5-1 plan.
- Filing timeliness: Transaction date June 18, 2026; Form 4 filed June 23, 2026 (five days later), which appears later than the typical two-business-day reporting window.
Context
- These transactions reflect vesting/conversion of equity awards (RSUs/PSUs) and a subsequent sale to cover tax withholding rather than a market-driven investment decision. The presence of a 10b5-1 plan and the tax-withholding sale indicates routine administration of compensation-related shares, not necessarily a directional signal about the insider’s view of the company.